Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where A. Giglio is active.

Publication


Featured researches published by A. Giglio.


The American Journal of Gastroenterology | 2010

Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study

Antonio Tursi; G. Brandimarte; Alfredo Papa; A. Giglio; Walter Elisei; Gian Marco Giorgetti; Giacomo Forti; Sergio Morini; Cesare Hassan; Maria Antonietta Pistoia; S. Rodinò; Teresa D'Amico; Ladislava Sebkova; N. Saccà; Emilio Di Giulio; Francesco Luzza; Maria Imeneo; Tiziana Larussa; Salvatore Di Rosa; Vito Annese; Silvio Danese; Antonio Gasbarrini

OBJECTIVES:VSL#3 is a high-potency probiotic mixture that has been used successfully in the treatment of pouchitis. The primary end point of the study was to assess the effects of supplementation with VSL#3 in patients affected by relapsing ulcerative colitis (UC) who are already under treatment with 5-aminosalicylic acid (ASA) and/or immunosuppressants at stable doses.METHODS:A total of 144 consecutive patients were randomly treated for 8 weeks with VSL#3 at a dose of 3,600 billion CFU/day (71 patients) or with placebo (73 patients).RESULTS:In all, 65 patients in the VSL#3 group and 66 patients in the placebo group completed the study. The decrease in ulcerative colitis disease activity index (UCDAI) scores of 50% or more was higher in the VSL#3 group than in the placebo group (63.1 vs. 40.8; per protocol (PP) P=0.010, confidence interval (CI)95% 0.51–0.74; intention to treat (ITT) P=0.031, CI95% 0.47–0.69). Significant results with VSL#3 were recorded in an improvement of three points or more in the UCDAI score (60.5% vs. 41.4%; PP P=0.017, CI95% 0.51–0.74; ITT P=0.046, CI95% 0.47–0.69) and in rectal bleeding (PP P=0.014, CI95% 0.46–0.70; ITT P=0.036, CI95% 0.41–0.65), whereas stool frequency (PP P=0.202, CI95% 0.39–0.63; ITT P=0.229, CI95% 0.35–0.57), physicians rate of disease activity (PP P=0.088, CI95% 0.34–0.58; ITT P=0.168, CI95% 0.31–0.53), and endoscopic scores (PP P=0.086, CI95% 0.74–0.92; ITT P=0.366, CI95% 0.66–0.86) did not show statistical differences. Remission was higher in the VSL#3 group than in the placebo group (47.7% vs. 32.4%; PP P=0.069, CI95% 0.36–0.60; ITT P=0.132, CI95% 0.33–0.56). Eight patients on VSL#3 (11.2%) and nine patients on placebo (12.3%) reported mild side effects.CONCLUSIONS:VSL#3 supplementation is safe and able to reduce UCDAI scores in patients affected by relapsing mild-to-moderate UC who are under treatment with 5-ASA and/or immunosuppressants. Moreover, VSL#3 improves rectal bleeding and seems to reinduce remission in relapsing UC patients after 8 weeks of treatment, although these parameters do not reach statistical significance.


Clinical Therapeutics | 2001

Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study

Francesco Luzza; A. Giglio; Enrico Ciliberto; Angelo Belmonte; Cesare Cavaliere; N. Saccà; Chiara Frandina; R. Fiocca; Vincenzo Trimboli; Francesco Pallone

BACKGROUND The optimal treatment regimen for eradication of Helicobacter pylori in patients with duodenal ulcer has yet to be determined. Based on a search of MEDLINE, no studies have been performed comparing a proton pump inhibitor-based triple therapy regimen with a ranitidine bismuth citrate (RBC)-based dual therapy regimen, both containing clarithromycin. OBJECTIVE This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer. METHODS Patients were randomized to receive either 1 week of triple therapy with LAN 30 mg BID, clarithromycin 500 mg BID, and tinidazole 500 mg BID, followed by 3 weeks of LAN 30 mg BID, or 2 weeks of dual therapy with RBC 400 mg BID plus clarithromycin 500 mg BID, followed by 2 weeks of RBC 400 mg BID. Eradication of H pylori was defined as negative results on both the urease quick test and histologic examination > or =4 weeks after the end of treatment. Duodenal healing and recurrence rates were assessed endoscopically at 8 weeks and 6 months. A per-protocol (PP) analysis was conducted for each efficacy end point. Also conducted were an intent-to-treat (ITT) analysis in which patients with missing data were considered failures, and an observed analysis (OBS), which included patients with an evaluable result after treatment, regardless of compliance. RESULTS One hundred eighty-five patients (126 men, 59 women; age range, 18-76 years; mean age, 43 years) were enrolled and randomized to treatment. In the LAN and RBC groups, respectively, H. pylori eradication rates were 92.6%, 93.1%, and 72.8% versus 78.6%, 77.9%, and 64.5% in the PP (P = 0.02), OBS (P = 0.01), and ITT analyses. The corresponding duodenal ulcer healing rates were 98.6%, 98.7%, and 83.7% versus 90.8%, 91.5%, and 81.7%; these differences were not statistically significant. Side effects were mild, occurring in 20.7% of LAN patients and 17.2% of RBC patients. Ulcer recurred in 2 RBC patients. No difference was observed between treatments in terms of the occurrence of gastritis or improvement of symptoms. CONCLUSION Based on the results of the PP and OBS analyses, LAN-based triple therapy was superior to RBC-based dual therapy for the eradication of H. pylori in patients with duodenal ulcer.


The American Journal of Gastroenterology | 2010

What's Hot in the Red Journal This Month

Antonio Tursi; Giovanni Brandimarte; Alfredo Papa; A. Giglio; Walter Elisei; Gian Marco Giorgetti; Giacomo Forti; Sergio Morini; Cesare Hassan; Maria Antonietta Pistoia; S. Rodinò; Teresa D'Amico; Ladislava Sebkova; N. Saccà; Emilio Di Giulio; Francesco Luzza; Maria Imeneo; Tiziana Larussa; Salvatore Di Rosa; Vito Annese; Silvio Danese; Antonio Gasbarrini

Probiotic therapy is attractive to the lay public for many reasons, including its perception as a “natural” remedy. VSL#3 is a probiotic mixture that has been used successfully in the treatment of ulcerative colitis (UC)-associated pouchitis. The investigators in this study assessed the effects of supplementation with VSL#3 in patients with relapsing mild-to-moderate UC treated with stable doses of 5-aminosalicylic acid (5-ASA) and/or immunosuppressive therapy. Subjects were randomly assigned to treatment with VSL#3 (3,600 billion colony-forming units per day) or placebo for 8 weeks. Sixty-five patients in the VSL#3 group and 66 patients in the placebo group completed the study. By intention-to-treat analysis, a 50% or greater decrease in ulcerative colitis disease activity index (UCDAI) scores was observed more frequently in the VSL#3 group than in the placebo group (63.1 vs. 40.8, 95% CI 0.47–0.69); however, stool frequency, physicians’ rating of disease activity, and endoscopic scores failed to achieve statistical differences. Eight patients taking VSL#3 (11.2%) and nine patients on placebo (12.3%) reported mild side effects. In conclusion, VSL#3 supplementation was found to be safe and to be associated with a reduction in UCDAI scores among patients with relapsing mild-to-moderate UC who were on stable doses of 5-ASA and/or immunosuppressants. See page 2218


Endoscopy | 1997

REFLUX ESOPHAGITIS : A COMPLICATION OF HELICOBACTER PYLORI ERADICATION THERAPY?

N. Saccà; A. De Medici; S. Rodinò; M. De Siena; A. Giglio


Digestive and Liver Disease | 2005

An unintentional ingestion of a toothpick: a case report.

N. Saccà; S. Rodinò; T. D’Amico; A. Fragomeni; Ladislava Sebkova; A. Giglio


Endoscopy | 1995

NSAIDS-induced digestive hemorrhage and esophageal pseudotumor : a case report

N. Saccà; S. Rodinò; A. De Medici; M. De Siena; A. Giglio


Inflammatory Bowel Diseases | 1996

Low Prevalence of p-ANCA in Unaffected Relatives of Patients with Ulcerative Colitis from a Mediterranean Area.

Giovanni Monteleone; Raffaella Marasco; Tiziana Parrello; Antonio De Medici; A. Giglio; Patrizia Doldo; Francesco Luzza; Francesco Pallone


Gastroenterology | 2009

388 Supplementation with the Probiotic VSL#3 in Patients with Mild-to-Moderate Active Ulcerative Colitis: A Double-Blind, Randomized, Placebo-Controlled Study

Antonio Tursi; Giovanni Brandimarte; Alfredo Papa; A. Giglio; Walter Elisei; GianMarco Giorgetti; Giacomo Forti; Silvio Danese; Antonio Gasbarrini


Endoscopy | 1994

Multiple Esophageal Ulcerations Caused by a Granular Formulation of Aspirin

S. Rodinò; N. Saccà; A. De Medici; A. Giglio


Digestive and Liver Disease | 2010

P.182 ENDOSCOPIC TREATMENT OF WATERMELON STOMACH: ARGON PLASMA COAGULATION VERSUS BAND LIGATION

Ladislava Sebkova; N. Saccà; T. D'Amico; S. Rodinò; A. Giglio

Collaboration


Dive into the A. Giglio's collaboration.

Top Co-Authors

Avatar

Francesco Luzza

Health Science University

View shared research outputs
Top Co-Authors

Avatar

Antonio Gasbarrini

Catholic University of the Sacred Heart

View shared research outputs
Top Co-Authors

Avatar

Silvio Danese

Catholic University of the Sacred Heart

View shared research outputs
Top Co-Authors

Avatar

Alfredo Papa

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar

Antonio Tursi

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar

Francesco Pallone

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar

Vito Annese

Casa Sollievo della Sofferenza

View shared research outputs
Top Co-Authors

Avatar

Walter Elisei

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Sergio Morini

University of Illinois at Chicago

View shared research outputs
Top Co-Authors

Avatar

Maria Imeneo

Health Science University

View shared research outputs
Researchain Logo
Decentralizing Knowledge